NI202000099A - Compuestos de purinona y su uso en el tratamiento del cáncer - Google Patents

Compuestos de purinona y su uso en el tratamiento del cáncer

Info

Publication number
NI202000099A
NI202000099A NI202000099A NI202000099A NI202000099A NI 202000099 A NI202000099 A NI 202000099A NI 202000099 A NI202000099 A NI 202000099A NI 202000099 A NI202000099 A NI 202000099A NI 202000099 A NI202000099 A NI 202000099A
Authority
NI
Nicaragua
Prior art keywords
compounds
salts
cancer
treatment
treating
Prior art date
Application number
NI202000099A
Other languages
English (en)
Inventor
Raymond Verschoyle Finlay Maurice
Woolf Goldberg Frederick
Richard HOWARD Martin
Kuan Tsuei Ting Attilla
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI202000099A publication Critical patent/NI202000099A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La memoria descriptiva se refiere en general a compuestos de Fórmula (I): (I) y sales farmacéuticamente aceptables de los mismos, en los que R1, A1, A2 y A3 tienen cualquiera de los significados definidos en el presente documento. La memoria descriptiva también se refiere al uso de dichos compuestos y sales de los mismos para tratar o prevenir la enfermedad mediada por PC-ADN, incluyendo el cáncer. La memoria descriptiva se refiere además a composiciones farmacéuticas que comprenden dichos compuestos y sales; kits que comprenden tales compuestos y sales; métodos de fabricación de dichos compuestos y sales; intermedios útiles en la fabricación de dichos compuestos y sales; y a los métodos para tratar una enfermedad mediada por PC-ADN, incluyendo el cáncer, usando dichos compuestos y sales.
NI202000099A 2018-06-15 2020-12-10 Compuestos de purinona y su uso en el tratamiento del cáncer NI202000099A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862685325P 2018-06-15 2018-06-15

Publications (1)

Publication Number Publication Date
NI202000099A true NI202000099A (es) 2021-09-24

Family

ID=67107385

Family Applications (1)

Application Number Title Priority Date Filing Date
NI202000099A NI202000099A (es) 2018-06-15 2020-12-10 Compuestos de purinona y su uso en el tratamiento del cáncer

Country Status (29)

Country Link
US (2) US11884671B2 (es)
EP (1) EP3807278B1 (es)
JP (1) JP7472044B2 (es)
KR (1) KR20210020944A (es)
CN (1) CN112236431B (es)
AR (1) AR114971A1 (es)
AU (1) AU2019287295B2 (es)
BR (1) BR112020025127A2 (es)
CA (1) CA3102195A1 (es)
CL (1) CL2020003131A1 (es)
CO (1) CO2020015758A2 (es)
CR (1) CR20200620A (es)
DO (1) DOP2020000241A (es)
EA (1) EA202190006A1 (es)
EC (1) ECSP20080276A (es)
ES (1) ES2931448T3 (es)
IL (1) IL279370A (es)
JO (1) JOP20200315A1 (es)
MA (1) MA52886A (es)
MX (1) MX2020013570A (es)
NI (1) NI202000099A (es)
PE (1) PE20210003A1 (es)
PH (1) PH12020552148A1 (es)
SG (1) SG11202012035WA (es)
TW (1) TWI820146B (es)
UA (1) UA126837C2 (es)
UY (1) UY38263A (es)
WO (1) WO2019238929A1 (es)
ZA (1) ZA202100195B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202110849A (zh) * 2019-05-27 2021-03-16 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑
JP7383818B2 (ja) * 2019-11-25 2023-11-20 ザイ ラボ （シャンハイ） カンパニー、リミテッド． Ｄｎａ－ｐｋ阻害剤としてのピリミドイミダゾル系化合物
WO2021136461A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
CN113121538B (zh) * 2019-12-31 2023-04-21 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
CN113121574B (zh) * 2019-12-31 2023-02-17 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的用途
TWI765640B (zh) * 2020-04-10 2022-05-21 大陸商南京明德新藥研發有限公司 作為dna-pk抑制劑的氨基嘧啶化合物及其衍生物
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
CN116406272A (zh) * 2020-07-20 2023-07-07 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
WO2022135360A1 (zh) * 2020-12-21 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
CN114656487B (zh) * 2020-12-22 2023-11-14 江苏恒瑞医药股份有限公司 稠合嘧啶类化合物、其制备方法及其在医药上的应用
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
WO2022135555A1 (zh) * 2020-12-24 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
CN116917288A (zh) * 2021-03-22 2023-10-20 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
WO2023274310A1 (zh) * 2021-06-29 2023-01-05 成都百裕制药股份有限公司 嘌呤衍生物的晶型及其药物组合物
CN117940437A (zh) * 2021-09-07 2024-04-26 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536841A (ja) * 2007-08-23 2010-12-02 アストラゼネカ アクチボラグ 増殖性疾患治療のためのｔｔｋ／ｍｐｓ１阻害剤としての２−アニリノプリン−８−オン類
US8591943B2 (en) * 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
RU2553681C2 (ru) 2009-10-29 2015-06-20 Вектура Лимитед N-содержащие гетероарильные производные в качестве ингибиторов jak3 киназы
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
PE20140405A1 (es) * 2011-03-11 2014-03-22 Gilead Calistoga Llc Terapias combinadas para malignidades hematologicas
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
JOP20190151B1 (ar) * 2016-12-20 2023-09-17 Astrazeneca Ab مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان

Also Published As

Publication number Publication date
MX2020013570A (es) 2021-05-27
KR20210020944A (ko) 2021-02-24
ES2931448T3 (es) 2022-12-29
UY38263A (es) 2019-12-31
PH12020552148A1 (en) 2021-07-05
JOP20200315A1 (ar) 2020-12-07
AU2019287295A1 (en) 2021-02-04
WO2019238929A1 (en) 2019-12-19
CN112236431A (zh) 2021-01-15
US20210171525A1 (en) 2021-06-10
CO2020015758A2 (es) 2021-04-30
CR20200620A (es) 2021-03-09
JP2021527095A (ja) 2021-10-11
PE20210003A1 (es) 2021-01-05
TWI820146B (zh) 2023-11-01
US11884671B2 (en) 2024-01-30
UA126837C2 (uk) 2023-02-08
CL2020003131A1 (es) 2021-04-30
AU2019287295B2 (en) 2022-05-26
EA202190006A1 (ru) 2021-03-29
SG11202012035WA (en) 2021-01-28
US20240150355A1 (en) 2024-05-09
CN112236431B (zh) 2024-02-13
ECSP20080276A (es) 2021-01-29
EP3807278B1 (en) 2022-08-31
DOP2020000241A (es) 2021-04-30
BR112020025127A2 (pt) 2021-03-23
CA3102195A1 (en) 2019-12-19
EP3807278A1 (en) 2021-04-21
AR114971A1 (es) 2020-11-11
ZA202100195B (en) 2022-08-31
TW202035410A (zh) 2020-10-01
JP7472044B2 (ja) 2024-04-22
IL279370A (en) 2021-01-31
MA52886A (fr) 2021-04-21

Similar Documents

Publication Publication Date Title
NI202000099A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CO2018004933A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
ECSP109934A (es) Compuesto - 946
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
NI201900094A (es) COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
CO2018010951A2 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")